Table 1.
Patient characteristics: age, final diagnosis for malignant and benign lesions and subtypes of invasive cancers given
| Age | Years |
| Mean | 58.4 |
| Standard deviation | 8.1 |
| Range | 49–75 |
| Final Diagnosis | Percentage (n = 199) |
| Malignant | |
| Invasive ductal carcinoma | 22.1 |
| Invasive lobular carcinoma | 4.0 |
| Ductal carcinoma in situ | 2.5 |
| Invasive mucinous carcinoma | 0.5 |
| Invasive micropapillary carcinoma | 0.5 |
| Benign | |
| Fibroadenoma | 5.5 |
| Simple cyst | 19.1 |
| Reactive changes / benign | 1.5 |
| Apocrine changes / metaplasia | 3.5 |
| Papilloma | 1.5 |
| Superposition | 28.1 |
| Cillindrical cell changes | 2.0 |
| Old hematoma | 0.5 |
| Inflammation | 0.5 |
| Intramammary lymphnode | 2.0 |
| Sclerosing adenosis | 1.0 |
| Atypical lobular hyperplasia | 0.5 |
| Ductectasia | 1.0 |
| Fibrosis | 1.5 |
| Ductal hyperplasia | 1.0 |
| Lobular carcinoma in situ | 0.5 |
| Flat epithelial atypia | 0.5 |
| Total | 100.0 |
| Invasive breast cancer subtypes | Percentage of all invasive cancers |
| ER positive | 92.3 |
| PR positive | 80.8 |
| HER2/neu positive | 12.2 |
| Grade 1 | 27.3 |
| Grade 2 | 47.3 |
| Grade 3 | 25.5 |
ER: estrogen receptor, PR: progesterone receptor, HER2/neu: Human Epidermal growth factor Receptor 2